AC
CLMT icon

Armistice Capital’s Calumet Specialty Products CLMT Stock Holding History

Armistice Capital’s Portfolio CLMT Stock Details CLMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,335
Closed -$263K – 352
2026
Q1 		$263K Buy
+7,335
New +$190K ﹤0.01% 203

Other funds holding CLMT

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WDOM
Wasserstein Debt Opportunities Management New York $264M AUM 188.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Adams Asset Advisors Dallas, Texas $882M AUM 42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Armistice Capital's CLMT Position: Q2 2026 in Review

Armistice Capital sold out of Calumet Specialty Products (CLMT) in Q2 2026, closing a stake of 7,335 shares — an estimated $263K sold.

Armistice Capital first reported a position in CLMT in Q1 2026 and held it in 1 quarter. The position peaked at $263K in Q1 2026. 188 funds tracked by Wall St. Rank hold CLMT as of Q2 2026.

  • Armistice Capital reported no remaining Calumet Specialty Products position as of Q2 2026 after selling out during the quarter.
  • Armistice Capital sold 7,335 Calumet Specialty Products shares in Q2 2026, an estimated $263K.
  • Armistice Capital first reported a position in Calumet Specialty Products in Q1 2026 and held it in 1 quarter.
  • Armistice Capital's Calumet Specialty Products position peaked at $263K in Q1 2026.
  • 188 funds tracked by Wall St. Rank held Calumet Specialty Products as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.